Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.

Arakawa M, Ebato C, Mita T, Hirose T, Kawamori R, Fujitani Y, Watada H

Biochemical and biophysical research communications21 Oct 2009Cited by 52 (Europe PMC)

PMID19836346DOI10.1016/j.bbrc.2009.10.054PepBankPUB-19836346

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice, short-term high-dose exendin‑4 transiently stimulated beta-cell proliferation.
In plain wordsIn mice, short-term high-dose exendin‑4 briefly increased insulin-producing cell growth.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBeta-cell proliferation
Study
mousen: not reported in source
C57BL/6J mice
Outcome group
Glycemic control · Metabolic and weight
Studied dose
High dose · Short-termAs given in this study (mouse).
Source sentences
Summary
Short-term administration of high-dose exendin-4 transiently stimulated beta-cell proliferation.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the beta-cell preserving actions of GLP-1R agonists, we assessed the acute and chronic effects of exendin-4 on beta-cell proliferation, mass and glucose tolerance in C57BL/6J mice under various conditions.
Report a problemFND-1983634601
02AnimalAnimal study (in vivo)Mechanism
In mouse islets, transcriptomic analysis after exendin‑4 showed increased IGF-1 receptor expression and downstream effectors.
In plain wordsIn mice, exendin‑4 increased IGF-1 receptor and related pathway expression in pancreatic islets.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseIGF-1 receptor pathway expression
Study
mousen: not reported in source
C57BL/6J mice
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Comparative transcriptomic analysis showed upregulation of IGF-1 receptor and its downstream effectors in islets.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the beta-cell preserving actions of GLP-1R agonists, we assessed the acute and chronic effects of exendin-4 on beta-cell proliferation, mass and glucose tolerance in C57BL/6J mice under various conditions.
Report a problemFND-1983634602
03AnimalAnimal study (in vivo)Efficacy outcome
In high-fat-fed mice, daily exendin‑4 for 4 weeks inhibited weight gain.
In plain wordsIn high-fat-fed mice, exendin‑4 reduced weight gain.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight gain
Study
mousen: not reported in source
C57BL/6J mice
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Treatment of mice with exendin-4 daily for 4 weeks (long-term administration) and feeding high-fat diet resulted in significant inhibition of weight gain and improvement of glucose tolerance with reduced insulin secretion and beta-cell mass.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the beta-cell preserving actions of GLP-1R agonists, we assessed the acute and chronic effects of exendin-4 on beta-cell proliferation, mass and glucose tolerance in C57BL/6J mice under various conditions.
Report a problemFND-1983634603
04AnimalAnimal study (in vivo)Efficacy outcome
In high-fat-fed mice, daily exendin‑4 for 4 weeks improved glucose tolerance.
In plain wordsIn high-fat-fed mice, exendin‑4 improved glucose tolerance.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGlucose tolerance
Study
mousen: not reported in source
C57BL/6J mice
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Treatment of mice with exendin-4 daily for 4 weeks (long-term administration) and feeding high-fat diet resulted in significant inhibition of weight gain and improvement of glucose tolerance with reduced insulin secretion and beta-cell mass.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the beta-cell preserving actions of GLP-1R agonists, we assessed the acute and chronic effects of exendin-4 on beta-cell proliferation, mass and glucose tolerance in C57BL/6J mice under various conditions.
Report a problemFND-1983634604
05AnimalAnimal study (in vivo)Efficacy outcome
In high-fat-fed mice, daily exendin‑4 for 4 weeks reduced insulin secretion.
In plain wordsIn high-fat-fed mice, exendin‑4 reduced insulin secretion.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInsulin secretion
Study
mousen: not reported in source
C57BL/6J mice
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Treatment of mice with exendin-4 daily for 4 weeks (long-term administration) and feeding high-fat diet resulted in significant inhibition of weight gain and improvement of glucose tolerance with reduced insulin secretion and beta-cell mass.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the beta-cell preserving actions of GLP-1R agonists, we assessed the acute and chronic effects of exendin-4 on beta-cell proliferation, mass and glucose tolerance in C57BL/6J mice under various conditions.
Report a problemFND-1983634605
06AnimalAnimal study (in vivo)Efficacy outcome
In high-fat-fed mice, daily exendin‑4 for 4 weeks reduced beta-cell mass.
In plain wordsIn high-fat-fed mice, exendin‑4 reduced insulin-producing cell mass.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBeta-cell mass
Study
mousen: not reported in source
C57BL/6J mice
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Treatment of mice with exendin-4 daily for 4 weeks (long-term administration) and feeding high-fat diet resulted in significant inhibition of weight gain and improvement of glucose tolerance with reduced insulin secretion and beta-cell mass.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the beta-cell preserving actions of GLP-1R agonists, we assessed the acute and chronic effects of exendin-4 on beta-cell proliferation, mass and glucose tolerance in C57BL/6J mice under various conditions.
Report a problemFND-1983634606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.